Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.42 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732641 | 0.84 | ACE (0.47) | CYP1A2PREP | |
| SCHEMBL5732581 | 0.82 | FKBP1A (0.49) | FKBP1APREP | |
| SCHEMBL21340465 | 0.79 | FKBP1A (0.55) | POLBMEN1KMT2AFKBP1AMMEL1 | |
| SCHEMBL5733042 | 0.78 | FKBP1A (0.54) | POLBMEN1KMT2AFKBP1AMMEL1 | |
| SCHEMBL9436236 | 0.78 | FKBP1A (0.54) | POLBMEN1KMT2AFKBP1AMMEL1 | |
| SCHEMBL18815613 | 0.76 | KLK7 (0.58) | KMT2AFKBP1APREP | |
| SCHEMBL18815610 | 0.76 | KLK7 (0.58) | KMT2AFKBP1APREP | |
| SCHEMBL18845568 | 0.75 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL21340466 | 0.74 | FKBP1A (0.53) | POLBMEN1KMT2AFKBP1AMMEL1 | |
| SCHEMBL10182552 | 0.73 | HPGD (0.52) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973518-B1 | SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES | UNIV ILLINOIS (US) | 2006-03-29 | — | — | EP | disclosed |
| US-6841530-B2 | Semi-synthetic studies toward didemnin analogues | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-01-11 | — | — | US | disclosed |
| EP-0973518-A4 | SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES | UNIV ILLINOIS (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20020037835-A1 | Semi-synthetic studies toward didemnin analogues | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2002-03-28 | — | — | US | disclosed |
| US-20010007855-A1 | SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2001-07-12 | — | — | US | disclosed |
| EP-0973518-A1 | SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998017275-A1 | SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007855-A1 | SEMI-SYNTHETIC STUDIES TOWARD DIDEMNIN ANALOGUES | FAR1, FASN, GOT1 | POLB 203/4885MEN1 35/4885KMT2A 1281/4885 |
| US-20020037835-A1 | Semi-synthetic studies toward didemnin analogues | FAR1, FASN, GOT1 | POLB 203/4885MEN1 35/4885KMT2A 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.